CBD for athletes:
A natural way to recover
I’ve always known that I wanted to be a professional hockey player. Like most pro athletes, my dreams were clear at a young age. When I wasn’t watching hockey, I was playing on the outdoor rink or stick handling in the garage. My commitment to strengthening my skills was evident, and my family was always […]
Creso Pharma to enter US CBD market through strategic acquisition
3 February 2022 Creso Pharma to enter US CBD market through strategic acquisition of established US-based business, Sierra Sage Herbs LLC and leading Green Goo brand Highlights: Membership Purchase Interest Agreement executed to acquire US-based Sierra Sage Herbs LLC (“SSH”) a female founded and family operated Certified B CORP – provides Creso Pharma with established, […]
Creso Pharma Announces Three New Board Appointments
Creso Pharma Announces Next Phase of Execution Spearheaded by Three New Appointments Mr William Lay, previously Executive Vice President – Strategy, Origination & Operations at Creso Pharma appointed as Group CEO and Managing Director Leading cannabis and psychedelics entrepreneur Bruce Linton appointed as Non-Executive Director (through end of year to accelerate execution) Mr Linton co-founded and […]
Halucenex Life Sciences invited to become Special Access Program drug supplier
reso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is
pleased to advise that wholly-owned, Canadian based psychedelics subsidiary, Halucenex Life Sciences
Inc. (“Halucenex”) has been invited to register as a potential supplier to Health Canada’s Special Access
Program (“SAP”), following recent regulatory changes.
Mernova Medicinal Inc. on track to achieve quarter-on-quarter revenue growth
Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to provide the following update on revenue growth through wholly-owned, Canadian subsidiary Mernova Medicinal Inc. (“Mernova”). During the current quarter, Mernova has generated C$612,734 in revenue, leaving the division well placed to continue quarter-on-quarter growth. Q4 CY2021 sales also add to the business division’s year to date revenue, which is C$2,979,797.
Halucenex Life Sciences Inc. awarded Dealer’s License Amendment from Health Canada
Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is
pleased to advise that wholly-owned, Canadian based psychedelics company, Halucenex Life Sciences
Inc. (“Halucenex”) has secured an amendment to its Controlled Drugs and Substances Dealer’s Licence
from Health Canada (“Dealer’s Licence”) on 29 November 2021 (refer ASX announcement: 16 August
ImpACTIVE signs LOI with Ohio-based Massage Therapist
ImpACTIVE Holdings Ltd. is pleased to announce it has secured an LOI with Ohio-based massage therapist, The Kneading Lotus, for the purchase of 150 units of ImpACTIVE’s Pro ReLEAF CBD-Only Roll-On application. Co-Founder Kevin Tansey was a frequent client of The Kneading Lotus during his time playing for the Toledo Walleye of the ECHL, and […]
ImpACTIVE to enter Canadian Recreational Cannabis Market
ImpACTIVE Holdings Ltd. is pleased to announce it’s intentions to apply for Health Canada licensing as a Cannabis Health Product and list on the Canadian Recreational Cannabis Markets pursuant to a Letter of Intent and strategic partnership with Creso Pharma Ltd. (previously announced March 9th, 2021).